(Date:12/4/2008)...h anniversary of drive to eliminate lymphatic fila...zole tablet and grant to The Carter Center , ,...rstCall/ -- In a meeting today with former U.S. Pr...rter, as well as global health thought leaders fro...SK ) announced that it has made a $250,000 donatio...
(Date:12/4/2008)...ewswire/ -- Two researchers who translate math int...n stopping breast cancer in its,tracks are this y...tific,Distinction in basic research and clinical ...onio, Susan G. Komen for the Cure(R) announced tod...in/prnh/20070122/NYM084LOGO ) , Award recip...
(Date:12/4/2008)...c. 4 MiddleBrook,Pharma... that it has opened its,administrative and sales ...wn,facility will continue to house certain person...ch and development group. The newly leased 14,971...se up to 60 employees as MiddleBrook,grows. , ...
(Date:12/4/2008)...., Dec. 4 Universal Heal...oday that they have expanded their,Board of Trust... Vice,President of Universal Health Services, Inc...ears of experience in healthcare leadership roles.... Co-head of the Acute Care Division,since 2007 an...
Breaking Medicine News(10 mins):Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 2Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 3Health News:GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program 4Health News:Susan G. Komen for the Cure(R) Announces Recipients of 2008 Komen Brinker Award for Scientific Distinction 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 2Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 3Health News:Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas 4(Date:12/3/2008)...wire/ -- Roche today announced that the U.S. Food ... guidance on the requirements for the Biologics Li...b), the first interleukin-6 (IL-6) receptor-inhibi... of adult patients with moderately to severely act...sult of the FDA,s evolving Risk Evaluation and Mit...
(Date:12/3/2008)...PRNewswire/ -- The Leukemia & Lymphoma Society...ing of a new clinical trial of ISF35, a cancer vac... (UCSD). , , LLS is collaborating on this...ment and approval of a novel approach aimed at tre...17p deleted chronic lymphocytic leukemia (CLL). ,...
(Date:12/3/2008)...Newswire-FirstCall/ -- Isis Pharmaceuticals,Inc....Pharmaceuticals, Inc.,provided positive survival ...f,OGX-011 in combination with docetaxel and predn...nd prednisone alone ("the control arm") for first-...rostate cancer. The current 10.6,month median ov...
(Date:12/2/2008)...USNewswire/ -- Researchers using functional,MRI (...ea of the brain,responsible for suppressing memor...ess-related psychiatric disorders. Results of the ...ng of the Radiological Society of North America,(...n and other stress-related disorders,traumatic m...
Breaking Medicine Technology:Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 2The Leukemia & Lymphoma Society and Memgen Announce New Chronic Lymphocytic Leukemia Clinical Trial 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Higher Risk of Death for Babies Born Just a Few Weeks Early Study Finds 6149 1Higher Risk of Death for Babies Born Just a Few Weeks Early Study Finds 6149 2Cardiome To Release Third Quarter Results 6147 1Cardiome To Release Third Quarter Results 6147 2Cardiome To Release Third Quarter Results 6147 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 1Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 2Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 3Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 4Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 5Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs 840 6Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Lamictal 28R 29 6145 1Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Lamictal 28R 29 6145 2... 66.1 weeks for the,satraplatin arm compared with ...0.64 (95% CI: 0.51-0.79, p<0.001), representing,a ...sion, MARTINSRIED/MUNICH, Germany, May 21, 2007 /P...ER, Colo. -- GPC Biotech AG and,Pharmion Corporati...data from the double-blind, randomized satraplatin...
...ut of ten patients taking,once-daily Lialda remain...N, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A,...ion study (303),presented at the British Society o...and in March 2007 showed Shire plc,s,Lialda(mesala...ients. Today, secondary endpoints of study 303 wer...
Other Medicine Technology:Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 2Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 3Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 4Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 5Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 2Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 3Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 4Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 5Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 6Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 7Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term,Safety Study of Lialda (mesalamine) Presented at DDW 8Merocel Ophthalmic Products provide the surgeon with fiber free products for fluid,control and safe cleaning of fine microsurgical instruments. The exclusive Merocel,material is highly absorbent,
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box.
Accu-Temp Cauteries provide a broad selection of tip styles for cauterization in a wide variety of ophthalmic procedures. Each single use cautery is packaged sterile, complete with a safety cap to lo
Medicine Products: